New combo therapy aims to tackle tough lymphoma
NCT ID NCT06160843
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether combining pembrolizumab (an immunotherapy) with olaparib (a targeted drug) can shrink tumors in people with peripheral T-cell lymphoma that has come back or not responded to treatment. About 24 adults in Singapore will receive the drugs intravenously and orally every three weeks. The study measures how many patients respond, how long they live, and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab (immunotherapy) and olaparib (targeted drug)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with hard-to-treat peripheral T-cell lymphoma.
- What could go wrong
- This is a small, early-phase trial with only 24 participants. The drugs may cause side effects or fail to shrink tumors. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Centre, Singapore
RECRUITINGSingapore, 168583, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.